Moreover, experience with BRAF inhibition is lacking in the treatment of ECD worldwide, although the current results of this treatment option in a small patient cohort appear promising with an objective of sustained clinical improvement and good tolerability [6]. This evidence concerns the gene BRAF and familial atrioventricular septal defect.